Heptares Therapeutics Limited

Nxera Pharma UK Limited

Francesca Deflorian

Miles Stuart Congreve

John Andrew Christopher

Mark Pickworth

Jonathan Stephen Mason

Sarah Joanne Bucknell

Giles Albert Brown

Julie Elaine Cansfield

Andrew David Cansfield

Nigel Alan Swain

Stephen Philippe Andrews

Stephen Paul Watson

Michael Alistair O'brien

Gregory R Ott

Andrea Bortolato

The disclosures herein relate to novel compounds of Formula (1); and salts thereof, wherein A, A, Q, X, R, Rand Rare defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with CGRP receptors.

CGRP antagonist compounds

The disclosures herein relate to novel compounds of Formula (1a): and salts thereof, wherein W, Z, L, Rand Rare defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with CGRP receptors.

The disclosures herein relate to novel compounds of formula

CGRP receptor antagonists

The disclosures herein relate to novel compounds of formula wherein R, R, Rand Rare as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.

The disclosures herein relate to novel compounds of formula wherein R, Rand Rare as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.

The disclosures herein relate to novel compounds of formula wherein Arand Rare as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.

Growing community of inventors

Cambridge, United Kingdom

Francesca Deflorian